Form 4: Vericel Corp: Chief Medical Officer Jonathan Hopper Reports Stock Option and Restricted Stock Unit Grants

Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp, reports the acquisition of stock options and restricted stock units on February 20, 2025.

Summary

• On February 20, 2025, Jonathan Mark Hopper, the Chief Medical Officer of Vericel Corp, reported the acquisition of 35,000 stock options and 14,000 restricted stock units (RSUs).
• The stock options have an exercise price of $54.31 and will vest in equal quarterly installments over four years, starting February 20, 2025.
• The RSUs represent a contingent right to receive one share of Vericel Corporation common stock each.
• The RSUs vest in four annual installments, beginning on February 20, 2026, and continuing on February 20, 2027, February 20, 2028, and February 20, 2029.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of equity grant is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are standard practice for executive compensation in publicly traded companies, particularly in the biotech sector.
• Vesting schedules of four years are also typical to ensure long-term alignment with company performance.
• Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The equity grants align the Chief Medical Officer's interests with those of the shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Vericel Corp, Jonathan Hopper, Chief Medical Officer, Stock Options, Restricted Stock Units, RSU, Vesting, Form 4, Insider Trading